1. Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population.
- Author
-
Nakagawa K, Matsumura K, Scory T, Farris MS, Larkin-Kaiser KA, Kikkawa H, Ivanova JI, and Wilner KD
- Subjects
- Antineoplastic Combined Chemotherapy Protocols pharmacology, Bayes Theorem, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung mortality, ErbB Receptors antagonists & inhibitors, ErbB Receptors genetics, Gain of Function Mutation, Humans, Japan epidemiology, Lung Neoplasms diagnosis, Lung Neoplasms genetics, Lung Neoplasms mortality, Neoplasm Staging, Network Meta-Analysis, Progression-Free Survival, Protein Kinase Inhibitors pharmacology, Randomized Controlled Trials as Topic, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Protein Kinase Inhibitors therapeutic use
- Abstract
Background: Five EGFR -tyrosine kinase inhibitors ( EGFR TKIs) are currently available in the first-line setting for non-small-cell lung cancer (NSCLC) in Japan. The aim here was to compare the relative efficacy of EGFR TKIs in the Japanese population. Materials & methods: A systematic review identified randomized controlled trials examining the efficacy of first-line EGFR TKIs. A Bayesian network meta-analysis was used to assess these EGFR TKI comparisons for progression-free survival (PFS). Results: A total of seven randomized controlled trials were identified and considered for network meta-analysis. Dacomitinib showed a trend toward improved PFS versus all comparators. Conclusion: Dacomitinib demonstrated a trend toward improved PFS and therefore, should be considered one of the standard first-line therapies for Japanese patients diagnosed with EGFR+ non-small-cell lung cancer.
- Published
- 2021
- Full Text
- View/download PDF